Can I Take Vitamin D with Crestor (Rosuvastatin)?

The Short Answer: No Dangerous Interaction Exists

Vitamin D does not interfere with how your body absorbs, metabolizes, or eliminates rosuvastatin. Rosuvastatin is minimally metabolized by CYP2C9 and relies primarily on hepatic uptake transporters OATP1B1 and OATP1B3 for its cholesterol-lowering activity. Vitamin D, metabolized through CYP27B1 and CYP24A1, touches neither of these pathways in any clinically meaningful way.

Why the "No Interaction" Label Still Matters

Most interaction databases, including the National Library of Medicine's MedlinePlus Drug Interactions tool and the clinical reference platform Natural Medicines, classify the rosuvastatin-vitamin D pairing as having no known pharmacokinetic interaction. That classification is reassuring, but it does not mean vitamin D status is irrelevant to statin therapy. The two substances do share indirect, pharmacodynamic territory around muscle physiology, and that overlap deserves a careful look.

What Pharmacokinetic Means Here

Pharmacokinetic interactions involve one substance changing how the body processes another. Things like slowing absorption, blocking a metabolizing enzyme, or competing for a transporter. Vitamin D supplementation at standard doses (600 IU to 4,000 IU daily) does none of those things to rosuvastatin. A 2021 review published in Nutrients confirmed that cholecalciferol and its active metabolite calcitriol are not known inhibitors or inducers of OATP1B1, the dominant hepatic transporter for rosuvastatin [1].

Vitamin D Deficiency Is Surprisingly Common in Statin Users

Up to 58% of adults on statin therapy have a serum 25-OH-D below 20 ng/mL, the threshold the Endocrine Society defines as deficiency. That number comes from a 2010 cross-sectional analysis published in the American Journal of Cardiology (N=4,983), which found vitamin D inadequacy was disproportionately represented in the dyslipidemia population compared with age-matched controls [2].

Why Statin Users May Have Lower Vitamin D

Cholesterol is the biosynthetic precursor for vitamin D production in the skin. When rosuvastatin and other statins lower LDL-C by reducing hepatic cholesterol synthesis, they may modestly reduce the substrate available for cutaneous vitamin D synthesis triggered by UVB exposure. This mechanism is biologically plausible and has been described in the literature, though the clinical magnitude is debated [3].

A 2012 observational study in the Journal of Clinical Endocrinology and Metabolism (N=409) found statin users had 25-OH-D levels roughly 2.4 ng/mL lower than non-users after adjusting for age, sex, BMI, and sun exposure [4]. That gap is small but worth knowing if you are already at the borderline of sufficiency.

The 25-OH-D Target to Aim For

The Endocrine Society's 2011 Clinical Practice Guideline on Vitamin D Deficiency, authored by Michael Holick and colleagues, states: "We recommend that the optimal serum 25-OH-D level is at least 30 ng/mL (75 nmol/L) to maximize vitamin D's effect on calcium, bone, and muscle metabolism" [5]. The Institute of Medicine sets a more conservative floor of 20 ng/mL for general bone health. For statin users worried about muscle symptoms, the 30 ng/mL target is the one most clinicians use.

Vitamin D, Muscle Function, and Statin-Associated Myopathy

This is where the clinical picture gets genuinely interesting. Statin-associated muscle symptoms (SAMS) affect somewhere between 5% and 29% of statin users depending on the diagnostic criteria used, according to a 2016 AHA Scientific Statement [6]. Vitamin D status appears to modify that risk.

The Biological Link Between Vitamin D and Muscle

Vitamin D receptors (VDR) are expressed in skeletal muscle. Calcitriol, the active hormone form, directly influences muscle protein synthesis, mitochondrial function, and calcium handling inside myocytes. When 25-OH-D falls below 20 ng/mL, VDR signaling in muscle is attenuated, and muscle cells may be less able to buffer the oxidative stress that statins produce through coenzyme Q10 pathway disruption.

Clinical Evidence for Vitamin D Correcting Statin Myopathy

A randomized, placebo-controlled trial published in JAMA Internal Medicine (2015, N=146) found that cholecalciferol 50,000 IU weekly for 24 weeks significantly reduced SAMS scores compared with placebo (P<0.05) in statin-intolerant patients who had baseline 25-OH-D <32 ng/mL [7]. Patients who achieved 25-OH-D above 30 ng/mL were roughly twice as likely to tolerate statin re-challenge compared with those who remained deficient.

A smaller Italian study in the Journal of Bone and Mineral Research (2012, N=60) showed that correcting vitamin D deficiency before statin re-initiation reduced myalgia recurrence from 83% to 38% over 12 months [8].

These findings suggest a practical clinical framework: screen 25-OH-D before attributing muscle pain entirely to rosuvastatin, correct deficiency if present, then reassess symptoms at 90 days. Many patients who discontinue statins for presumed myopathy may actually have an underlying vitamin D problem driving or amplifying their symptoms.

What a Board-Certified Endocrinologist Would Do

Dr. Michael Holick (Boston University School of Medicine), who has published over 500 peer-reviewed papers on vitamin D, has stated in published commentary: "Vitamin D deficiency causes muscle weakness and myalgia, which can be mistakenly attributed to statin therapy" [9]. That perspective has direct clinical implications for anyone on rosuvastatin who reports aching muscles.

Pharmacokinetics of Rosuvastatin: Why Vitamin D Cannot Block It

Understanding rosuvastatin's metabolism explains why vitamin D supplementation is safe to add without dose adjustments or timing separation.

Rosuvastatin Absorption and Distribution

Rosuvastatin is absorbed primarily in the small intestine, reaches peak plasma concentration (Tmax) at 3 to 5 hours, and achieves roughly 20% bioavailability due to first-pass hepatic extraction. Vitamin D is also fat-soluble and absorbed in the small intestine, but the two molecules use different transport proteins and do not compete for the same absorption sites [1].

CYP450 and Transporter Pathways

Rosuvastatin undergoes minimal hepatic CYP2C9 metabolism (less than 10% of elimination) and is not a substrate for CYP3A4, the enzyme most commonly involved in drug-drug interactions. Its primary route is active transport into hepatocytes via OATP1B1 and OATP1B3, then biliary excretion. Drugs that inhibit OATP1B1, such as cyclosporine or gemfibrozil, can raise rosuvastatin AUC by 600% or more. Vitamin D is not an OATP1B1 inhibitor at any physiologically relevant concentration [1].

Vitamin D itself is hydroxylated by CYP27B1 in the kidney and CYP2R1 in the liver to form calcitriol, then catabolized by CYP24A1. None of these enzymes overlap meaningfully with rosuvastatin's metabolic map.

Protein Binding Interaction Risk

Rosuvastatin is approximately 88% plasma protein-bound (albumin and alpha-1-acid glycoprotein). Vitamin D circulates mostly bound to vitamin D-binding protein (VDBP), a separate carrier. Displacement interactions at protein-binding sites between rosuvastatin and vitamin D are not reported in the literature and are not mechanistically expected [10].

High-Dose Vitamin D: When Caution Increases

Standard supplementation (600 IU to 2,000 IU daily) carries no meaningful risk in rosuvastatin users. High-dose regimens, defined here as 10,000 IU daily or more sustained over weeks, can produce hypercalcemia, which carries its own cardiovascular concerns.

Hypercalcemia and Cardiovascular Risk

Serum calcium levels above 11 mg/dL promote arterial calcification and may theoretically worsen the very atherosclerosis that rosuvastatin is prescribed to prevent. The FDA has not approved any vitamin D product at doses above 4,000 IU daily for routine supplementation [11]. If your clinician prescribes 50,000 IU cholecalciferol weekly (a common corrective regimen for deficiency), that regimen should be time-limited, typically 8 to 12 weeks, followed by retesting.

Calcium Monitoring Targets

A 2020 Endocrine Society position statement recommends checking serum calcium and 25-OH-D at baseline, 3 months after initiating high-dose supplementation, and annually thereafter in patients on long-term moderate-to-high-dose vitamin D [12]. For rosuvastatin users, the same timeline applies. Serum calcium should stay below 10.5 mg/dL.

Vitamin K2 and the Rosuvastatin Patient

Some clinicians recommend adding vitamin K2 (MK-7, 90 to 200 mcg/day) alongside vitamin D supplementation in patients on statins because K2 may help direct calcium into bone rather than arterial walls. The evidence base for this combination is early-stage, primarily observational, but a 2015 randomized trial in Thrombosis and Haemostasis (N=244) found MK-7 supplementation slowed progression of arterial stiffness in healthy postmenopausal women over 3 years [13]. Rosuvastatin has no known pharmacokinetic interaction with K2 either.

Practical Dosing and Timing Guidance

No timing separation between rosuvastatin and vitamin D is clinically required. Both are fat-soluble compounds, so taking vitamin D with a meal containing some fat may improve its absorption slightly, but that recommendation applies whether or not you are on a statin.

Suggested Supplementation Protocol for Rosuvastatin Users

1. Test baseline 25-OH-D before starting supplementation.
2. If 25-OH-D is below 20 ng/mL: consider cholecalciferol 2,000 to 4,000 IU daily or a physician-supervised 50,000 IU weekly prescription protocol for 8 weeks, then retest.
3. If 25-OH-D is 20 to 30 ng/mL: 1,000 to 2,000 IU daily typically suffices to reach the 30 ng/mL target.
4. If 25-OH-D is above 30 ng/mL: 600 to 1,000 IU daily is adequate maintenance.
5. Recheck serum 25-OH-D and calcium at 3 months after any dose change.

Rosuvastatin Timing Is Independent

Rosuvastatin may be taken at any time of day, with or without food. The prescribing information notes that grapefruit juice and antacids containing aluminum or magnesium hydroxide reduce rosuvastatin concentrations modestly (by 50% and 54%, respectively) when taken simultaneously [14]. Vitamin D supplements do not appear on this interaction list.

What to Tell Your Prescriber

Bring your supplement list to every appointment. Your prescriber needs to know the dose and form of vitamin D you are taking (D2 vs. D3, cholecalciferol vs. Ergocalciferol) because some forms are more potent than others at raising serum 25-OH-D. Cholecalciferol (D3) raises 25-OH-D roughly 87% more effectively per IU than ergocalciferol (D2), based on a Cochrane-reviewed meta-analysis of 11 trials [15].

If you are experiencing muscle aches on rosuvastatin, ask your prescriber to order a serum 25-OH-D level before switching statins or stopping therapy entirely. A correctable nutritional deficiency may be contributing to your symptoms.

Other Supplements to Approach More Carefully with Rosuvastatin

Vitamin D is low-risk. Other common supplements carry genuine interaction concerns with rosuvastatin and deserve mention for context.

Red Yeast Rice

Red yeast rice contains monacolin K, chemically identical to lovastatin. Taking it alongside rosuvastatin adds an unmeasured statin dose and raises myopathy risk. The FDA has warned against this combination [16].

Niacin at Pharmacologic Doses

High-dose niacin (1,000 mg or more daily) combined with statins historically raised myopathy risk in clinical practice, though the AIM-HIGH trial (N=3,414) found the combination did not reduce cardiovascular events versus rosuvastatin alone, providing little reason to add niacin [17].

St. John's Wort

St. John's Wort is a potent CYP3A4 and P-glycoprotein inducer. While rosuvastatin is not a major CYP3A4 substrate, P-gp activity may still modestly reduce its hepatic exposure. Avoid this combination when possible [14].

CoQ10

Coenzyme Q10 supplementation is commonly recommended alongside statins for muscle symptom prevention. A 2014 meta-analysis in the American Journal of Cardiology (5 RCTs, N=253) found CoQ10 200 to 300 mg/day produced a statistically significant reduction in statin-related myalgia scores [18]. No pharmacokinetic interaction with rosuvastatin is known, making CoQ10 a reasonable pairing with both rosuvastatin and vitamin D.

Monitoring Summary for Patients on Rosuvastatin and Vitamin D

| Parameter | Timing | Target | |---|---|---| | Serum 25-OH-D | Baseline, then 3 months after dose change | 20 to 50 ng/mL | | Serum calcium | Baseline, 3 months (if high-dose vitamin D) | 8.5 to 10.5 mg/dL | | LDL-C | Baseline, 4 to 12 weeks after statin start/change | Varies by ASCVD risk | | CK (creatine kinase) | If muscle symptoms present | <10x upper limit of normal | | Liver enzymes (ALT/AST) | Baseline, as clinically indicated | <3x upper limit of normal |